NCT03518554View on ClinicalTrials.gov

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

February 3, 2022

Study Completion Date

February 3, 2022

Conditions
Non-small Cell Lung CancerHead and Neck CancerEsophageal CancerOther Metastatic Solid Tumors
Interventions
DRUG

JAB-3068

JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.

Trial Locations (4)

37203

Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute, Nashville

77030

The University of Texas M. D. Anderson Cancer Center, Houston

80202

HealthONE Clinic Services Oncology-Hematology, Denver

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY